Is cimzia the only biologic safe for breastfeeding?

Is Cimzia the only biologic considered safe during breastfeeding?

No. Cimzia (certolizumab pegol) is one of the better-supported biologics for breastfeeding, but it is not the only one considered compatible with nursing. Guidance across major societies generally focuses on whether a biologic is likely to pass into breast milk and, even more importantly, whether any drug that does enter milk is likely to be destroyed in the infant’s gut. Large antibody drugs such as monoclonal antibodies (including anti-TNF agents like certolizumab) tend to have low oral bioavailability for infants, which supports their use while breastfeeding.

What makes Cimzia (certolizumab pegol) stand out for breastfeeding?

Cimzia is often highlighted because certolizumab pegol lacks an Fc portion (it is an anti-TNF monoclonal antibody fragment with PEGylation), which is associated with very limited transfer into breast milk in available reports and expectations for infant exposure. This is why many clinicians consider it a preferred anti-TNF option during lactation compared with agents with different molecular structures.

Which other biologics are commonly used while breastfeeding?

Other biologics used for autoimmune conditions are frequently considered acceptable during breastfeeding, especially monoclonal antibodies used for conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. In practice, clinicians commonly consider:
- Other anti-TNF monoclonal antibodies (often with more caution than Cimzia depending on the specific agent and available transfer data)
- Non–anti-TNF monoclonal antibodies used for inflammatory diseases, where infant exposure is expected to be low because of low oral absorption and protein digestion

Whether a particular biologic is chosen can depend on the mother’s condition, the specific drug, and the strength of breastfeeding transfer/breast-milk data for that agent.

Are any biologics avoided or handled differently during lactation?

Some biologics are approached more cautiously if there’s evidence (or strong theoretical concern) for higher milk transfer, longer persistence in the infant, or limited breastfeeding-specific data. When clinicians are choosing among options, they tend to favor agents with:
- Lower or well-characterized transfer into milk
- Large protein structure that is likely to be broken down in the infant gut
- More lactation experience and published case/registry information

What do patients usually ask about: will my baby absorb the drug?

For most biologics used in breastfeeding, the key reassurance is that even if small amounts reach breast milk, the infant would have to absorb an active drug intact. Large antibody medications are generally broken down in the gastrointestinal tract, so systemic absorption by the infant is expected to be low.

Practical guidance: how should breastfeeding safety be decided for Cimzia vs alternatives?

Most recommendations are individualized. Clinicians generally compare biologics based on:
- The exact drug’s milk transfer and infant exposure information
- The mother’s disease control (switching drugs can destabilize symptoms)
- The availability of an alternative with better lactation data (Cimzia is often favored for anti-TNF therapy)

If you tell me which condition you’re treating (e.g., Crohn’s, rheumatoid arthritis, psoriasis) and whether you mean “safe enough to continue while breastfeeding” or “safest option,” I can narrow down which biologics are typically preferred alongside Cimzia.